References
- Small GW, Rabins PV, Barry PP, et al. Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer’s Association, and the American Geriatrics Society. J Am Med Assoc 1997;278:1363–71
- Fratiglioni L, Launer LJ, Andersen K, et al. Incidence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts [Neurologic Diseases in the Elderly Research Group]. Neurology 2000;54(Suppl 5):S10–S15
- Lobo A, Launer LJ, Fratiglioni L, et al. Prevalence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts [Neurologic Diseases in the Elderly Research Group]. Neurology 2000;54(Suppl 5):S4–S9
- Alzheimer Europe Online. Prevalence in Europe. Statistics. 2006
- Burns A, Rossor M, Hecker J, et al. The effects of donepezil in Alzheimer’s disease – results from a multinational trial. Dement Geriatr Cogn Disord 1999;10:237–44
- Gauthier S, Feldman H, Hecker J, et al. Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer’s disease. Curr Med Res Opin 2002;18:347–54
- Mohs RC, Doody RS, Morris JC, et al. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 2001;57:481–8
- Rogers SL, Doody RS, Mohs RC, et al. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study [Donepezil Study Group]. Arch Intern Med 1998;158:1021–31
- Rogers SL, Farlow MR, Doody RS, et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease [Donepezil Study Group]. Neurology 1998;50:136–45
- Winblad B, Engedal K, Soininen H, et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001;57:489–95
- Boada-Rovira M, Brodaty H, Cras P, et al. Efficacy and safety of donepezil in patients with Alzheimer’s disease: results of a global, multinational, clinical experience study. Drugs Aging 2004;21:43–53
- Doody RS, Geldmacher DS, Gordon B, et al. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Arch Neurol 2001;58:427–33
- Hager K, Calabrese P, Frolich L, et al. An observational clinical study of the efficacy and tolerability of donepezil in the treatment of Alzheimer’s disease. Dement Geriatr Cogn Disord 2003;15:189–98
- Klinger T, Ibach B, Schoenknecht P, et al. Effect of donepezil in patients with Alzheimer’s disease previously untreated or treated with memantine or nootropic agents in Germany: an observational study. Curr Med Res Opin 2005;21:723–32
- Folstein MF, Folstein SE, McHugh PR. ‘Mini-mental state’. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–98
- Holmes C, Wilkinson D, Dean C, et al. The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. Neurology 2004;63:214–9
- Rockwood K, Graham JE, Fay S; ACADIE Investigators. Goal setting and attainment in Alzheimer’s disease patients treated with donepezil. J Neurol Neurosurg Psychiatry 2002;73:500–7
- Donaldson C, Tarrier N, Burns A. The impact of the symptoms of dementia on caregivers. Br J Psychiatry 1997;170:62–8